Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Uprosertib |
Trade Name | |
Synonyms | GSK2141795|GSK-2141795|GSK 2141795 |
Drug Descriptions |
Uprosertib (GSK2141795) is an ATP-competitive inhibitor of AKT, which leads to inhibition of PI3K/AKT signaling potentially resulting in inhibition of cell proliferation and anti-tumor growth (PMID: 24978597, PMID: 32062691). |
DrugClasses | Akt Inhibitor (Pan) 21 AKT Inhibitor (Pan) - ATP competitive 7 |
CAS Registry Number | 1047634-65-0 |
NCIT ID | C84870 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cisplatin + Uprosertib | Cisplatin Uprosertib | 0 | 0 |
Dabrafenib + Trametinib + Uprosertib | Dabrafenib Trametinib Uprosertib | 0 | 1 |
Dabrafenib + Uprosertib | Dabrafenib Uprosertib | 0 | 1 |
Tipifarnib + Uprosertib | Tipifarnib Uprosertib | 1 | 0 |
Trametinib + Uprosertib | Trametinib Uprosertib | 0 | 8 |
Uprosertib | Uprosertib | 2 | 0 |